Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Franzone

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
The Canadian Journal of Cardiology|August 14, 2025
Early Hemodynamic Performance of the SAPIEN 3 Ultra Resilia and Evolut Valves: A Propensity-Matched AnalysisMarisa Avvedimento, Silvia Mas-Peiro, Suleman Aktaa, et al.
JAMA Cardiology|June 24, 2026
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-AnalysisAndrea Zito, Antonio Landi, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Structural Heart : the Journal of the Heart Team|July 24, 2025
Understanding Aortic Stenosis and Transcatheter Aortic Valve Replacement in WomenGiulia Masiero, Anna Franzone, Valeria Paradies, et al.
American Heart Journal|August 12, 2023
Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCIRaffaele Piccolo, Paolo Calabrò, Attilio Varricchio, et al.
Journal of the American College of Cardiology|July 5, 2023
P2Y<sub>12</sub> Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary EventsFelice Gragnano, Davide Cao, Leah Pirondini, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
The Canadian Journal of Cardiology|August 14, 2025
Early Hemodynamic Performance of the SAPIEN 3 Ultra Resilia and Evolut Valves: A Propensity-Matched AnalysisMarisa Avvedimento, Silvia Mas-Peiro, Suleman Aktaa, et al.
JAMA Cardiology|June 24, 2026
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-AnalysisAndrea Zito, Antonio Landi, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Structural Heart : the Journal of the Heart Team|July 24, 2025
Understanding Aortic Stenosis and Transcatheter Aortic Valve Replacement in WomenGiulia Masiero, Anna Franzone, Valeria Paradies, et al.
American Heart Journal|August 12, 2023
Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCIRaffaele Piccolo, Paolo Calabrò, Attilio Varricchio, et al.
Journal of the American College of Cardiology|July 5, 2023
P2Y<sub>12</sub> Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary EventsFelice Gragnano, Davide Cao, Leah Pirondini, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Pageof 18